Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.93 USD
Change Today +0.62 / 4.66%
Volume 1.2M
HALO On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

H. Michael Shepard Ph.D.

Chief Scientific Officer and Vice President, Halozyme Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 8 board members in 1 different organizations across 2 different industries.

See Board Relationships
As of Fiscal Year 2013


Dr. H. Michael Shepard, Ph.D. founded Receptor BioLogix, Inc. in 2003 and has been its President and Chief Scientific Officer since June 2006. Dr. Shepard served as the Chief Scientific Officer and Vice President of Halozyme Therapeutics, Inc. since December 3, 2010. He served as Vice President Of Discovery Research at Halozyme Therapeutics, Inc., from June 2009 to December 3, 2010. He served as Chief Executive Officer of Receptor BioLogix Inc. He has an extensive background ...

Read Full Background

Corporate Headquarters*

11388 Sorrento Valley Road
San Diego, California 92121

United States

Phone: 858-794-8889
Fax: 858-704-8311

Board Members Memberships*

Founder, President, Chief Scientific Officer and Director


Unknown/Other Education
Indiana University, Bloomington
Indiana University, Bloomington
Bachelor's Degree
University of California - Davis School of Law

Other Affiliations*

Annual Compensation*

Total Annual Compensation$321,360

Stock Options*

Restricted Stock Awards$176,850
All Other Compensation$17,804
Exercisable Options193,017
Exercisable Options Value$1,400,383
Unexercisable Options84,394
Unexercisable Options Value$577,667
Total Value of Options$1,978,049
Total Number of Options277,411

Total Compensation*

Total Annual Cash Compensation$596,252
Total Short Term Compensation$321,360
Other Long Term Compensation$194,654
Total Calculated Compensation$952,909
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $13.93 USD +0.62


Yongfeng Zhang Ph.D.Chief Executive Officer, Chief Science Officer and Director
Amphastar Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at